Potent cytodifferentiating agents related to hexamethylenebisacetamide - Wikidata - wikimedia - TriplyDB

Potent cytodifferentiating agents related to hexamethylenebisacetamide

Potent cytodifferentiating agents related to hexamethylenebisacetamide

http://www.wikidata.org/entity/Q37537900

about

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug A porphobilinogen deaminase (PBGD) Ran-binding protein interaction is implicated in nuclear trafficking of PBGD in differentiating glioma cells Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process.A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.Polar/apolar compounds induce leukemia cell differentiation by modulating cell-surface potential Discovery and development of SAHA as an anticancer agent.The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.Lead optimization of HMBA to develop potent HEXIM1 inducers.Adsorption properties of polar/apolar inducers at a charged interface and their relevance to leukemia cell differentiation.Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog.Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors.

P2860

Q28142463-A726F878-CAD3-4657-AF97-64B55E007519 Q28282479-DF05DBBD-21D3-4877-8887-BBF190032DD1 Q28577898-E535F9C0-6598-4F00-A48C-ACE1A8F304FB Q34725469-D29ECF09-5682-4848-BC70-3404C440D0F1 Q35133494-AECA15E0-6C95-4B92-8578-9854F1989D58 Q35844125-72A977E4-1B45-41E6-AEE2-BED5AE09506D Q35976663-ED095AC5-C204-468C-AA6C-B92C766837E3 Q36379695-0529573A-81A0-4A56-9B72-F2BED34EE5D3 Q36745383-897866E9-8F94-44CD-A219-9B20FAED49B1 Q37315202-DF63F0C5-7820-4DAF-9ED9-584AFC99CDBC Q37550149-E34FB65F-0CC9-4996-B636-517827DB9D29 Q37696194-472180A0-B7A3-4FC0-9588-499EAEB6F3D2 Q39662579-E9538E0B-6646-410F-AA42-487D06D93ECB Q40521844-D1E97FCF-C74D-43C1-835F-0D842D7BCEC2 Q41863296-379452FE-8626-4623-8077-C217C88BF09F Q47199869-22263F51-7175-4F24-9E43-9B76E76C7D2A

P2860

Potent cytodifferentiating agents related to hexamethylenebisacetamide

http://www.wikidata.org/entity/Q37537900

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 1991

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Potent cytodifferentiating agents related to hexamethylenebisacetamide

@en

Potent cytodifferentiating agents related to hexamethylenebisacetamide.

@nl

type

label

Potent cytodifferentiating agents related to hexamethylenebisacetamide

@en

Potent cytodifferentiating agents related to hexamethylenebisacetamide.

@nl

prefLabel

Potent cytodifferentiating agents related to hexamethylenebisacetamide

@en

Potent cytodifferentiating agents related to hexamethylenebisacetamide.

@nl

P1433

Q37537900-4A839CD8-EF9E-404F-B7BB-E15BE473EB9D

P1476

Q37537900-BBB067AB-477F-4AF6-AA0F-8186F177DF2F

P2093

Q37537900-05018E29-E689-4649-A893-1809FC907847

Q37537900-28D49325-C357-44C8-8DDA-09A3E040BF91

Q37537900-6BE005B7-B729-450E-84BF-213DAE746CAE

Q37537900-786ADB75-3311-42D5-A290-9D4D247CB3D7

Q37537900-95010548-7C53-4FD2-B4F9-F4D5994E01F2

Q37537900-C94C2CD4-3BC7-4FA3-94B3-F43BB90829C4

Q37537900-F61247AF-7EF8-4D85-9608-565366A02211

Q37537900-F61D8381-AEEE-4BE2-8134-420A39ECE1DC

P2860

Q37537900-263CEC3A-DDCF-48CB-B354-57BFF184DF16

Q37537900-41B86E05-E20E-4B08-B7E4-FB4EB096CDD6

Q37537900-57F5E3A9-489B-4397-BC35-E79DC908EED8

Q37537900-5B9277B8-1DF1-4EB0-8A02-23606EED90FE

Q37537900-5FD1C80C-B8F3-422A-9E2F-FB7BADE4C10E

Q37537900-66331A48-0673-4C7A-BA2E-8EE42E3AF2D8

Q37537900-668AD1E5-2148-43D6-8046-5BFDD95B0F06

Q37537900-8166D31D-A5A5-433D-B6CE-D91AB46B7643

Q37537900-962C4E06-E81E-4476-AF72-9677570315A6

Q37537900-9A12707A-59ED-4980-8DA3-AB34361C42FD

P304

Q37537900-AC8192F6-D850-445A-B568-FB63E8B40ACD

P31

Q37537900-1CF35F60-75AB-4EFA-88B9-DCEFC49B99E2

P356

Q37537900-66ED5138-1295-4FB8-A8AE-2C711345BB6E

P407

Q37537900-42D551F9-E671-465F-BAE8-9C1B22819EB1

P433

Q37537900-573DBE9F-3057-4D57-BDD8-9425D1708A01

P478

Q37537900-591850FB-A845-43C3-935B-867354982391

P577

Q37537900-5D458CE8-FA5A-4858-BD83-58535B73BA61

P5875

Q37537900-BC836401-E066-4F8B-8CE0-9E0734D6B251

P698

Q37537900-984919EB-E7EF-4322-848B-B259887E7CEE

P932

Q37537900-623101EA-95B7-4838-951E-E81F51EB0A47

P356

PNAS.88.13.5542

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Potent cytodifferentiating agents related to hexamethylenebisacetamide

@en

P2093

B Jursic

http://www.w3.org/2001/XMLSchema#string

E Friedman

http://www.w3.org/2001/XMLSchema#string

L Leng

http://www.w3.org/2001/XMLSchema#string

L Ngo

http://www.w3.org/2001/XMLSchema#string

P A Marks

http://www.w3.org/2001/XMLSchema#string

R A Rifkind

http://www.w3.org/2001/XMLSchema#string

R Breslow

http://www.w3.org/2001/XMLSchema#string

Z F Yan

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.

Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.

Studies and perspectives of protein kinase C.

Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potential

Protein kinase C activity and hexamethylenebisacetamide-induced erythroleukemia cell differentiation

Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds

A new group of potent inducers of differentiation in murine erythroleukemia cells.

Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide.

Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.

Inducers of erythroleukemic differentiation. Relationship of structure to activity among planar-polar compounds.

P304

5542-5546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.88.13.5542

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

88

http://www.w3.org/2001/XMLSchema#string

P577

1991-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21092865

http://www.w3.org/2001/XMLSchema#string

P698

2062836

http://www.w3.org/2001/XMLSchema#string

P932

51913

http://www.w3.org/2001/XMLSchema#string